GlobeNewswire

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Share
  • Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and others to address root causes of disparities in health and education
  • This collaboration will create actionable solutions to target the systemic racism that drives inequitable health outcomes and work together for health equity progress through greater diversity, equity and inclusion across the research and development ecosystem

  • Novartis US Foundation plans to invest approximately $13.7 million to establish three digitally enabled research centers at Morehouse School of Medicine, including a clinical trial center of excellencethat could be a model for possible expansion to other HBCU medical schools, to increase diversity among clinical trial investigators and participants

  • Novartis US Foundation also plans to invest $20 million to help prepare up to 1,200 Black and African American students to become the next generation of leaders in health, science, technology and business in collaboration with Thurgood Marshall College Fund

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.

Leaders from these companies, organizations, and learning institutions have signed a pledge to co-develop programs focused on building trust in the health care system with communities of color and making measurable progress towards health equity. Working together with the communities they aim to impact, the collaboration will focus on improving access to high-quality education, technology, improved health outcomes, and promising jobs; increasing clinical trial and clinical trial investigator diversity; addressing inherent bias in the data standards used to diagnose and treat disease; and finding actionable solutions to environmental and climate issues that disproportionately affect health among communities of color.

“At Novartis, we envision a world with equity in health for all. Just as there are a multitude of factors and causes behind racial disparities in health and education, there is no single solution to this critical challenge. It will take the concerted, urgent action of diverse stakeholders across the public and private sectors,” said Vas Narasimhan, MD, CEO of Novartis. “We are honored and humbled to work together with these organizations to build enduring solutions to some of the most pressing, deeply rooted, and historic challenges in the United States, and we invite other like-minded companies and organizations to join us in creating this paradigm shift in health equity.”

Over an initial period of ten years, the collaboration will focus on four key areas:

  1. Enable the next generation of Black and African American leaders by creating equitable access to high quality education and professional development for future leaders, in health science, technology and business-related fields.
  2. Support the establishment of Digitally Enabled Clinical Trial Centers of Excellence, managed and led by clinical researchers of color, to build trust, increase diversity and inclusivity in clinical trials, and contribute to improved health outcomes for people of color.
  3. Research and validate existing data standards that drive diagnosis, clinical trial endpoints and population health policy to identify areas for increased inclusivity and ensure accurate data collection and unbiased treatment decisions.
  4. Establish Digitally Enabled Research Centers on the impact of the environment and climate change on health to identify solutions to environmental and climate issues that disproportionately affect communities of color.

All parties will spend the next six months co-creating programs with the communities, including establishing the first clinical trial, data standards, and environment, climate and health research centers at Morehouse School of Medicine. Each organization will bring its own expertise and resources to design and implement enduring solutions in these areas.

“Health equity is not only accessible healthcare for patients, but developing educational and professional opportunities to create a diverse pipeline of educators, clinicians and other professionals, as well as ensuring all are included in clinical studies,” said Valerie Montgomery Rice, MD, President and CEO, Morehouse School of Medicine. “This is a first of its kind collaboration and Morehouse School of Medicine is excited to work with Novartis and this coalition of medical schools, colleges, universities and other leading companies and organizations to create centers of excellence for clinical trials, data standards research, and environment and health research. We know that real change starts here, when work is done to make a significant impact on representation and inclusion.”

Health disparities affecting minority groups are endemic in the US, most recently demonstrated during the COVID-19 pandemic by the disproportionate rates of hospitalization and death in minority groups.1 Compared with non-Hispanic whites, the Black and African American community has a lower life expectancy, a higher mortality rate from cancer, a greater likelihood of diseases such as asthma, and significantly increased rates of maternal and infant mortality.2 Some of these health disparities are further exacerbated by increased exposure to negative environmental factors such as air pollution, excessive heat, and poorer water quality in communities of color.3

Health inequity extends to Black and African American underrepresentation across medical systems – not just among clinical trial participants but also among medical school students, physicians, and clinical trial investigators. In 2019, Black and African Americans comprised 13.4% of the US population but only 6.2% of medical school graduates,5% of practicing physicians, and an even smaller proportion of clinical trial investigators.4

“Black and African American people endured education and health disparities in the United States long before the COVID-19 pandemic. Their exclusion from the research and development ecosystem has resulted in mistrust and a delayed uptake of life-saving innovative medicines and effective care models, further exacerbating racial disparities in care and outcomes,” said Patrice Matchaba, MD, President of the Novartis US Foundation. “We are proud to come together to take our direction from Black and African American community members and other minority groups on programs that will help achieve sustained change.”

Enabling the next generation of Black and African American leaders
As an initial step, the Novartis US Foundation plans to invest $20 million in scholarships, mentorships and research grants over the next 10 years to help create equitable access to high quality education and professional development for HBCU students in health-related fields.

Administered by The Thurgood Marshall College Fund, the program will train and prepare up to 1,200 students:

  • Scholarships: Three-year scholarships of $10,000 a year for up to 360 students at select Historically Black Colleges, Universities and Medical Schools
  • Mentorships: Novartis employee volunteers will mentor up to 400 HBCU students, including the scholarship recipients, for a period of three years each, for a total of up to 1,200 students. Students also will receive career readiness and leadership development training
  • Internships: HBCU undergraduate and medical school students will be encouraged and supported to apply for the Novartis annual internship program
  • Research grants: Competitive faculty research grant program offering up to ten grants of $25,000 each year to HBCU faculty, focusing on actionable solutions to health equity issues

“We are pleased to work with Novartis to answer the calls for urgent action to address the role that systemic racism plays in health disparities among Black people,” said Harry L. Williams, EdD, President and CEO, Thurgood Marshall College Fund. “This kind of investment in HBCUs is critical to ensuring that Black students have opportunities to pursue influential roles in health, science and technology by eliminating barriers and creating pathways through mentorship and training.”

Participating Companies and Organizations
NovartisNovartis US Foundation
Thurgood Marshall College FundCoursera
National Medical Association


Participating HBCUs and Medical Schools
Alabama A&M UniversityMeharry Medical College
Bowie State UniversityMorehouse School of Medicine
Charles R Drew University of Medicine   and ScienceMorehouse College
Clark Atlanta UniversityMorgan State University
Delaware State UniversityNorth Carolina Agricultural &Technical State University
Dillard UniversityPrairie View A&M University
Fisk UniversitySouthern University and A&M College
Florida A&M UniversitySpelman College
Hampton UniversityTennessee State University
Howard University College of MedicineTexas Southern University
Howard UniversityTuskegee University
Jackson State UniversityUniversity of Maryland Eastern Shore
LeMoyne Owen CollegeXavier University of Louisiana
Lincoln University in Pennsylvania

Novartis commitment to diversity in clinical trials
Diversity in clinical trials is integral to who we are at Novartis. Our purpose is to reimagine medicine to improve and extend the lives of all people – inclusive of race, ethnicity, gender, age, sexual orientation, disability, location and socioeconomic status. Diverse, inclusive trials are critical to ensuring that we understand how those patients who are most likely to be treated for a disease or condition will respond to a medicine. Novartis is taking a proactive, science-driven approach to address barriers to clinical trial participation, such as identifying sites where diverse patients with a particular disease or condition may be located, identifying healthcare providers who treat underserved or underrepresented populations, and collaborating with researchers to address the goals of enrolling a diverse population in a clinical trial. To learn more about our Commitment to Diversity in Clinical Trials, please visit https://www.novartis.com/sites/www.novartis.com/files/commitment-for-diversity-in-clinical-trials.pdf.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “commitment,” “investigational,” “pipeline,” “launch,” “pledges,” “to target,” “to increase,” or similar terms, or by express or implied discussions regarding the activities and efforts described in this press release. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the activities and efforts described in this media update, including the collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools, will be completed, or will achieve any of its intended goals, or succeed in the expected time frame or at all. In particular, our expectations regarding the activities and efforts described in this press release, including such collaboration, could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

About the Novartis US Foundation
The Novartis US Foundation is a charitable organization established by Novartis to support philanthropic efforts in the United States. The mission of the Novartis US Foundation is to improve health in underserved communities in the US by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system. We do this by supporting sustainable programs and partnerships that strengthen health systems, eliminate barriers to quality health services, and enhance local communities.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

  1. https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/racial-ethnic-disparities/disparities-deaths.html
  2. https://www.minorityhealth.hhs.gov/
  3. Hsu, A., Sheriff, G., Chakraborty, T. et al. Disproportionate exposure to urban heat island intensity across major US cities. Nat Commun 12, 2721 (2021). https://doi.org/10.1038/s41467-021-22799-5
  4. Association of American Medical Schools: Diversity in Medicine: Facts and Figures 2019

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Julie Masow
Novartis US External Communications
+1 862 579 8456
julie.masow@novarts.com
Caryn Marshall
Novartis US External Communications
+1 201 213 3976
caryn.marshall@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Thomas Hungerbuehler        
Isabella Zinck
+41 61 324 8425
+41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nikkiso Cryogenic Services Recommissioned Air Separation Plant in India for Critical Oxygen Supply28.7.2021 02:30:00 CEST | Press release

TEMECULA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce they have completed the recommissioning of an Air Separation plant in Patancheru, Hyderabad India. This project was done in coordination with the Telangana government (TEL), and Greenko Foundation (GKO). Due to the ongoing pandemic crisis in India, the Indian government initiated a directive to restart the operation and LOX production to meet the urgent demands for medical oxygen. GKO has taken the old shut-down Oxygen plant on rental basis from Air Water India Private Limited (AWI) for period of (2) two years. In May 2021, the Group partnered along with GKO in recommissioning of the plant. Nikkiso Cryogenic Services provided critical technical support and spare parts, including nozzle actuators and vibration components, and Nikkiso Cosmodyne India Pvt. Ltd. provided field service support. Critica

Invitation to DNO Q2 2021 Earnings Call28.7.2021 00:31:28 CEST | Press release

Oslo, 28 July 2021 – DNO ASA, the Norwegian oil and gas operator, will publish its Q2 2021 operating and interim financial results on 29 July 2021 at 07:00 (CEST). A videoconference call with executive management will follow at 15:00 (CEST). Please visit www.dno.no for login details. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, United Kingdom, Netherlands, Ireland and Yemen. – This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Synchronoss Names Christina Gabrys Chief Legal Officer27.7.2021 22:05:00 CEST | Press release

BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital products and platforms, today announced the appointment of Christina “Chrissy” Gabrys as Chief Legal Officer. Gabrys succeeds Ronald Prague who is stepping down after 15 years with the company to pursue other interests. In her new role, Gabrys will oversee all legal affairs for the company. “Ron has played a significant role in shaping the Synchronoss that we are today. His leadership in negotiating and closing customer agreements, completing acquisitions and the company’s other financial endeavors – including his contribution to the successful recent recapitalization of the company – has been invaluable and he will be greatly missed,” said Jeff Miller, President and CEO of Synchronoss. “I would like to thank Ron for all he’s contributed to the business. We will always consider him part of the Synchronoss family and wish him w

SBM Offshore signs FPSO Almirante Tamandaré contracts27.7.2021 18:37:16 CEST | Press release

July 27, 2021 SBM Offshore is pleased to announce it has signed contracts with Petróleo Brasileiro S.A. (Petrobras) for the 26.25 years lease and operation of FPSO Almirante Tamandaré. These contracts follow the signing of the binding Letter of Intent as announced on February 25, 2021. FPSO Almirante Tamandaré will be deployed at the Búzios field in the Santos Basin approximately 180 kilometers offshore Rio de Janeiro in Brazil. SBM Offshore is progressing with the design and construction using its industry leading Fast4Ward® program. Delivery of the FPSO is expected in the second half of 2024. CorporateProfile The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation. As of December 31, 2020, the Company employs approximately 4,570 people worl

Exel Industries :Third quarter 2020-2021 revenue : A sustained growth rate of 18.4%, in line with our expectations.27.7.2021 18:00:00 CEST | Press release

PRESS RELEASE July 27, 2021 Third quarter 2020-2021 revenue A sustained growth rate of 18.4%, in line with our expectations. Q3 revenue in €m2019 ‐ 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying99.6113.814.216.414.3%16.4%Sugar Beet Harvesters2230.68.68.839.3%39.9%Garden Watering and Spraying50.149.8-0.3-0.8-0.6%-1.6%Industrial Spraying38.85516.217.941.9%46.2%EXEL Industries Group210.4249.238.842.218.4%20.1% *like‐for‐like = at constant foreign exchange rates and scope 9-month revenue in €m2019 - 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying255.729236.342.114.2%16.5%Sugar Beet Harvesters53.863.81010.918.7%20.2%Garden Watering and Spraying89.3109.420.120.322.4%22.7%Industrial Spraying125.8169.243.43834.5%30.2%EXEL Industries Group524.7634.4109.8111.320.9%21.2% *like‐for‐like = at constant foreign exchange rates and scope Third quarte

Leasinvest Real Estate SA: Publication of a transparency notification27.7.2021 18:00:00 CEST | Press release

PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 27 July 2021 issued by AXA, shows a passive threshold overrun, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AXA in Leasinvest Real Estate has decreased to 13.44% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress AXA SA 25, Avenue Matignon, 75008 Paris, France TRANSACTION DATE: 19 July 2021 THRESHOLD DROPPED BELOW: 15% DENOMINATOR: 11,804,919 DETAILS OF THE NOTIFICAT

ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2021 RESULTS27.7.2021 18:00:00 CEST | Press release

Almere, The Netherlands July 27, 2021, 6 p.m. CET Continued robust market demand fuels strong quarterly performance ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2021 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2020 Q1 2021 Q2 2021 New orders 298.0 410.6 515.7 Revenue 341.8 394.0 411.7 Gross profit margin % 48.3 49.5 48.1 Operating result 87.6 124.5 118.4 Operating result margin % 25.6 31.6 28.7 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 10.7 13.9 19.3 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.3) (3.0) (3.0) Net earnings 74.1 122.5 108.4 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 77.4 125.5 111.4 New orders of €516 million for the second quarter 2021 increased by 73% compared to the same